Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Small Pharma Inc (DMT.VN)

Small Pharma Inc (DMT.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 50,366
  • Shares Outstanding, K 335,770
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,836 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.19
Trade DMT.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings $-0.02 on N/A
  • Latest Earnings Date 10/20/23
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.130 +15.38%
on 09/29/23
0.215 -30.23%
on 09/26/23
+0.020 (+15.38%)
since 09/20/23
3-Month
0.060 +150.00%
on 08/16/23
0.215 -30.23%
on 09/26/23
+0.085 (+130.77%)
since 07/20/23
52-Week
0.060 +150.00%
on 08/16/23
0.220 -31.82%
on 10/21/22
-0.060 (-28.57%)
since 10/20/22

Most Recent Stories

More News
Cybin to Acquire Small Pharma Inc.

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders...

DMTTF : 0.1117 (-9.70%)
DMT.VN : 0.150 (-6.25%)
CYBN.NE : 0.5200 (+1.96%)
Stocks in play: Small Pharma Inc.

Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment ...

DMT.VN : 0.150 (-6.25%)
Canadian Patent Grant Strengthens Small Pharma’s International Position

Further Composition of Matter protection for SPL028, the Company’s next candidate expected to enter the clinic...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- Small Pharma...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer

Building on strong foundations to take Small Pharma through development to commercial success Peter Rands to take on role as Chief Innovation &...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
Small Pharma Reports Fiscal First Quarter 2023 Highlights

Progress continues apace with multiple trials expected to enter clinic later this year First US patent granted LONDON, July 15, 2022 (GLOBE NEWSWIRE)...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

LONDON, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022

Reporting its financial results and continued progress across short-acting psychedelics portfolio Executive team and IP position strengthened LONDON,...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022

LONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)
Small Pharma Shares Business Update Ahead of Annual Financial Results

- Appointment of Alastair Riddell as COO- Two new Composition of Matter patents granted for pipeline projects- Progress continues across short-acting...

DMT.VN : 0.150 (-6.25%)
DMTTF : 0.1117 (-9.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.167
2nd Resistance Point 0.163
1st Resistance Point 0.157
Last Price 0.150
1st Support Level 0.147
2nd Support Level 0.143
3rd Support Level 0.137

See More

52-Week High 0.220
Fibonacci 61.8% 0.159
Last Price 0.150
Fibonacci 50% 0.140
Fibonacci 38.2% 0.121
52-Week Low 0.060

See More

Business Summary

Small Pharma Inc is a neuropharmaceutical company. It is committed towards the development of effective therapeutic treatments for mental health disorders. Small Pharma is developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar